doi: 10.1007/s10495-013-0956-x
During this meeting, the advisory committee will: Review available safety and efficacy data for BPC-157, including preclinical studies and any available clinical evidence Consider public comments submitted by patients, practitioners, and industry stakeholders Evaluate the clinical need for compounded BPC-157 and the patient populations that would benefit Assess the compounding quality considerations specific to peptide formulations Issue a recommendation to the FDA on whether BPC-157 should be included on the 503A compounding list Possible outcomes include: Positive recommendation: PCAC advises the FDA to add BPC-157 to the 503A list, clearing the way for legal compounding nationwide
A one percent GHK-Cu serum, ideally with liposomal or nano-lipid carriers, applied nightly for at least twelve weeks, is the safest entry point
Price can indicate quality as well
It has been suggested that phylloquinone (vitamin K 1, referred to as vitamin K in this study) is the main form in the liver, which is responsible for VKD carboxylation of coagulation factors, while menaquinones (vitamin K 2 ) are mainly distributed in other tissues for extrahepatic carboxylation 28
